Literature DB >> 15131768

Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.

E Rask1, T Olsson, S Söderberg, J j Holst Jj, A Tura, G Pacini, B Ahrén.   

Abstract

Subjects with impaired glucose tolerance (IGT) are usually overweight and exhibit insulin resistance with a defective compensation of insulin secretion. In this study, we sought to establish the interrelation between insulin secretion and insulin sensitivity after oral glucose in non-obese subjects with IGT and we also examined this interrelation in relation to the 2 main incretins, glucagon-like peptide (GLP-1) and gastric inhibitory polypeptide (GIP). To that end, 13 women with IGT and 17 women with normal glucose tolerance (NGT) underwent an oral glucose tolerance test (OGTT) with measurements of glucose, insulin, C-peptide, GLP-1, and GIP. Insulin secretion (TIS) and insulin sensitivity (OGIS) were assessed using models describing the relationship between glucose, insulin and C-peptide data. These models allowed estimation also of the hepatic extraction of insulin. The age (54.2 +/- 9.7 [mean +/- SD] years) and body mass index (BMI; 26.0 +/- 4.0 kg/m(2)) did not differ between the groups. Subjects with IGT displayed lower TIS during the initial 30 minutes after oral glucose (0.97 +/- 0.17 [mean +/- SEM] v 1.75 +/- 0.23 nmol/L in NGT; P =.018) and lower OGIS (397 +/- 21 v 463 +/- 12 mL/min/m(2); P =.005). The incremental 30-minute TIS times OGIS (reflecting insulin secretion in relation to insulin sensitivity) was significantly reduced in IGT (359 +/- 51 v 774 +/- 91 nmol/min/m(2), P =.001). This measure correlated inversely to the 2-hour glucose level (r = -0.71; P <.001). In contrast, TIS over the whole 180-minute period was higher in IGT (26.2 +/- 2.4 v 20.0 +/- 2.0 nmol/L; P =.035). Hepatic insulin extraction correlated linearly with OGIS (r = 0.71; P <.001), but was not significantly different between the groups although there was a trend with lower extraction in IGT (P =.055). Plasma levels of GLP-1 and GIP increased after oral glucose. Total secretion of these incretin hormones during the 3-hour test did not differ between the 2 groups. However, the 30-minute increase in GLP-1 concentrations was lower in IGT than in NGT (P =.036). We conclude that also in non-obese subjects with IGT, when adiposity is controlled for in relation to NGT, defective early insulin secretion after oral glucose is a key factor. This defective beta-cell function is associated with, and may be caused by, a reduced early GLP-1 response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131768     DOI: 10.1016/j.metabol.2003.11.011

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  33 in total

Review 1.  The role of incretin therapy at different stages of diabetes.

Authors:  Simona Cernea
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 2.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

Review 3.  Incretins and the development of type 2 diabetes.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

4.  Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

Authors:  J J Meier; B Gallwitz; M Askenas; K Vollmer; C F Deacon; J J Holst; W E Schmidt; M A Nauck
Journal:  Diabetologia       Date:  2005-07-12       Impact factor: 10.122

5.  Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test.

Authors:  Jonas B Møller; William J Jusko; Wei Gao; Torben Hansen; Oluf Pedersen; Jens J Holst; Rune V Overgaard; Henrik Madsen; Steen H Ingwersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-09-16       Impact factor: 2.745

6.  Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell.

Authors:  Gareth E Lim; Guan J Huang; Nina Flora; Derek LeRoith; Christopher J Rhodes; Patricia L Brubaker
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

7.  Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus.

Authors:  A L DePaula; A L V Macedo; N Rassi; S Vencio; C A Machado; B R Mota; L Q Silva; A Halpern; V Schraibman
Journal:  Surg Endosc       Date:  2008-03-18       Impact factor: 4.584

8.  Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35.

Authors:  A L DePaula; A L V Macedo; N Rassi; C A Machado; V Schraibman; L Q Silva; A Halpern
Journal:  Surg Endosc       Date:  2008-03       Impact factor: 4.584

9.  Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34.

Authors:  Aureo Ludovico DePaula; A L V Macedo; V Schraibman; B R Mota; S Vencio
Journal:  Surg Endosc       Date:  2008-10-02       Impact factor: 4.584

10.  Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats.

Authors:  Zhiyi Xie; Budbazar Enkhjargal; Lingyun Wu; Keren Zhou; Chengmei Sun; Xin Hu; Vadim Gospodarev; Jiping Tang; Chao You; John H Zhang
Journal:  Neuropharmacology       Date:  2017-10-04       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.